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Abstract
Objective: Autonomously functioning thyroid areas may be associated with subclinical or overt hyperthyroidism, 
but may exist even in the presence of normal TSH. This study was aimed at comparing the rate of autonomously 
functioning areas and their cardiac sequelae in patients with nodular goitre studied with the usual and a  
novel approach.
Design and methods: In total 490 adult outpatients with thyroid nodular goitre, living in a mild iodine-deficient 
area, were selected in our referral centre for thyroid diseases from 2009 to 2014 on the basis of a suspicion of thyroid 
functional autonomy. They were divided in three groups according to a non-conventional approach (excessive 
response to thyroxine treatment: group 1) or conventional approach (low/normal TSH with clinical suspicion or low 
TSH: groups 2 and 3). All patients of the study with the suspicion of thyroid functional autonomy underwent thyroid 
scan with radioactive iodine (I131) uptake (RAIU).
Results: The percentage of confirmed thyroid functional autonomy was 319/490, being significantly higher in group 
3 than in groups 1 and 2 (81.5 vs 64.7 vs 52.6%; chi-square P < 0.0001). However, the diagnosis with non-conventional 
approach was made at a significant earlier age (P < 0.0001). Cardiac arrhythmias as well as atrial fibrillation were 
similarly detected by conventional and non-conventional approaches (chi-square test: P = 0.2537; P = 0.8425).
Conclusions: The hyper-responsiveness to thyroxine treatment should induce the suspicion of thyroid functional 
autonomy at an early stage, allowing to detect autonomous functioning areas in apparently euthyroid patients.
Introduction
The natural history of nontoxic goitre, in areas of iodine 
deficiency, encompasses a progressive increase in size 
(diffuse goitre) and/or development of multiple nodules 
(nodular goitre, NG) (1, 2, 3). Despite its long-lasting 
euthyroid phase, thyroid functional autonomy may 
occur in both diffuse and NG, with greater frequency in 
the latter (6.4% vs 21.2%) (4). The progression towards 
thyroid autonomy depends on genetic predisposition, 
somatic mutations of TSH receptor, iodine intake and 
older age (1, 2).
Autonomously functioning thyroid nodule (AFTN) 
may not only be associated with subclinical or overt 
hyperthyroidism (2, 5), but also with a normal TSH level 
(6). Increased cardiovascular morbidity and mortality have 
been reported in patients with overt hyperthyroidism, 
as well as in those with subclinical hyperthyroidism 
(7). In addition, atrial arrhythmias (sinus tachycardia, 
atrial premature beats and atrial fibrillation) are frequent 
sequelae of overt hyperthyroidism (5). Similar effects on 
cardiac function have been described even in subclinical 
hyperthyroid patients (8, 9, 10), mostly in the elderly 
(11). Indeed, atrial fibrillation (12) is diagnosed in 2% of 
euthyroid people, 14% of overt hyperthyroid patients and 
13% of patients with subclinical hyperthyroidism (5, 13).
Radioiodine thyroid scan (TS) represents so far the 
gold standard to detect autonomously functioning 
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areas, and ATA guidelines suggest performing it in 
patients with low TSH (14). However, a recent meta-
analysis underlines the importance of TS also in goitrous 
patients with TSH within the normal references to 
detect autonomous areas (6). In fact, low serum TSH 
is present only in half of patients with autonomous 
thyroid functional areas, as ascertained with TS (6). 
This raises the question whether occult autonomous 
areas may be not diagnosed in multinodular goitres 
showing normal serum TSH. So, there is a need for an 
early recognition of these occult autonomous areas in 
the thyroid even to prevent the cardiac sequelae (15).
Serum TSH is a recognized growth factor for thyroid 
nodules (16). In iodine-deficient areas (17), thyroxine 
treatment is used as yet to lower TSH to prevent growth of 
nodules and the appearance of new ones (16, 18). However, 
the efficacy and appropriateness of this treatment has 
been challenged, mainly in iodine sufficient areas (2, 3, 
19), also due to side effects related to the use of high doses 
of thyroxine (5). To date, increasing evidence showed the 
importance of using an individually tailored thyroxine 
dose to reach more safely target TSH (20, 21, 22, 23).
This study aims to evaluate the potential reliability 
of the use of tailored LT4 dose in detecting AFTN. This 
non-conventional approach was compared, in terms 
of potential clinical sequelae, to the conventional one 
adopting TS in patients with low TSH.
Subjects and methods
Subjects
A total of 2940 Caucasian outpatients with thyroid NG, 
living in a mild iodine-deficient area, were examined 
in our referral centre for thyroid diseases from 2009 to 
2014. Of these, a total of 568 (19.3%) patients with NG 
were selected based on the following suspicious features 
of thyroid functional autonomy: (1) patients treated 
with levothyroxine (L-T4) that showed TSH less than the 
expected level (TSH target: 0.1–0.4 mU/L) or a TSH target 
with a L-T4 dose lower than the one observed in a carefully 
checked reference group (‘non-conventional’ suspicion); 
(2) untreated patients with TSH value in the lower part 
of the normal range (0.4–2.0 mU/L) in the presence of 
cardiovascular (i.e. increased heart rate, arrhythmia) 
and extra-cardiovascular symptoms (anxiety, irritability, 
etc.) (‘fairly conventional’ suspicion); (3) untreated 
patients with subnormal TSH value (<0.4 mU/L) and in 
the presence of clinical symptoms of hyperthyroidism 
(‘conventional’ suspicion).
Exclusion criteria were (a) overt hyperthyroidism; 
(b) autoimmune, factitious, post-inflammatory or 
iatrogenic hyperthyroidism; (c) recent use of iodine 
products and drugs able to affect thyroid function 
(24, 25); (d) lack of patient’s compliance; and 
(e) pregnancy and breastfeeding.
Based on these criteria, 78 patients were excluded and 
the remaining 490 patients represented the study group 
(384 female and 106 male, median age: 59  years): 156 
patients belonging to group 1 (136F/20M; median age: 
52 years), 188 belonging to group 2 (145F/43M; median 
age: 62  years) and 146 to group 3 (103F/43M; median 
age: 66 years) (Table 1). The diagnosis of NG was based 
on clinical and ultrasonographic features, as described 
previously (26). In adult patients belonging to group 
1, thyroxine treatment has been used to lower TSH, as 
still accepted in iodine-deficient areas in patients with 
evidence of non-neoplastic nodular growth (16, 17, 18). 
Elderly patients were in long-lasting treatment, either 
started previously in our institution or, more often, 
prescribed in other hospitals. In all patients, any side 
effect possibly related to thyroxine treatment has led to 
an immediate drug withdrawal.
The internal reference group, needed as a 
benchmark for thyroxine treatment, consisted of 124 
patients (110F/14M; median age: 54 years; 88 patients 
with less than 60 years and 36 patients with more than 
60 years) with nontoxic NG (NTNG) in semi-suppressive 
L-T4 treatment (serum TSH target: 0.1–0.4 mU/L). The 
individually daily thyroxine dose was titrated on the 
basis of patients’ body weight (kg) and age, as described 
previously (21, 26, 27). In this group, the presence of 
thyroid functional autonomy, gastrointestinal disorders 
and other major interferences (see Liwanpo for rev 
(25)) as well as cardiac disorders has been positively 
excluded. Patients belonging to the reference group 
and those with ‘non-conventional’ suspicion were 
educated to take thyroxine fasting since at least 3 h 
and to wait at least 1 h before ingest any food or drink, 
except water. Moreover, we informed patients to wait 
at least 3 h before to take other drugs, in order to avoid 
interferences with the absorption kinetic of thyroxine, 
according to more recent literature (28, 29, 30, 31). 
Table 1 Patients’ characteristics.
Group 1 Group 2 Group 3
Patients (n) 156 188 146
Sex (female/male) 136F/20M 145F/43M 103F/43M
Median age (years) 52 62 66
Median TSH (mU/L) 1.21 0.80 0.12
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A single levothyroxine brand was used in all treated 
patients (Eutirox – Bracco, Milan, Italy; since July 2013 
Merck Serono S.p.A.), to prevent possible differences in 
bioequivalence (32).
Design of the study
The 156 patients with NG in semi-suppressive thyroxine 
therapy (‘non-conventional’ suspicion, group 1) were 
subdivided into two age-related groups (adult <60 years 
and elderly >60 years) and each group has been compared 
with the corresponding age-related reference group 
(Table 2). This was done to avoid bias due to the lower T4 
requirement in elderly (1, 5). So far, in the adult reference 
group the desired serum TSH (median = 0.20 mU/L) was 
reached at a median L-T4 dose of 1.56 µg/kg/day. In the 
study group, despite the lower L-T4 dose (P < 0.0001), the 
adult patients exhibited a lower TSH level (P < 0.0001) 
(Table  2). Similar results were observed in the elderly 
patients: a median L-T4 dose of 1.33 µg/kg/day and a 
median serum TSH of 0.22 mU/L were observed in the 
reference group, while, in the study group, a significantly 
lower L-T4 dose (P < 0.0001) led to a median serum TSH 
of 0.07 mU/L (P = 0.0727) (Table 2). Hence, these patients 
were considered hyper-responsive to thyroid treatment 
regardless of age. Data were, thus, merged together 
and compared with those of goitrous patients with 
conventional suspicion of thyroid autonomy.
All patients of the study with the suspicion of thyroid 
functional autonomy underwent TS with radioactive 
iodine (I131) uptake (RAIU). Obviously, in the patients 
with ‘non-conventional’ suspicion, the L-T4 treatment 
was previously discontinued. When the results of TS 
were inconclusive, the patients underwent to a second 
TS and radioiodine uptake after triiodothyronine (T3) 
administration (20–25 µg for three times in the day, for 
8–10 days) (Werner’s test) (33).
Study has been conducted upon written informed 
consent and as part of the diagnostic and therapeutic 
workup of the patients involved, according to the local 
ethical rules and to the guidelines in the Declaration 
of Helsinki.
Methods
Serum TSH levels were measured by commercial kit 
(Thermo Scientific, BRAHMS TSH RIA) (normal range: 0.4–
4.0 mU/L; sensitivity: 0.04 mU/L; intra-assay and inter-
assay variation were 2.5% and 4.1%, respectively). Levels 
of serum free T4 were detected by commercial kit (Thermo 
Scientific, BRAHMS FT4 RIA) (normal range: 10–25 pmol/L, 
which is the equivalent of 0.78–1.94 ng/dL), as the levels 
of serum free T3 (normal range: 3.5–8.1 pmol/L or 2.3–
5.3 pg/mL). Serum anti-thyroid peroxidase antibodies 
(TPO-Ab) levels were detected by commercial kit (Thermo 
Scientific, BRAHMS anti-TPO) (normal range: <60 U/mL). 
The anti-TSHreceptor antibodies (TRAb) levels were 
measured by commercial kit (Thermo Scientific, BRAHMS 
TRAK Human RIA).
Statistical analysis
Data are expressed as median value (Interquartile range: 
IQ1 and IQ3) and were analysed by nonparametric 
Mann–Whitney U test. The differences among the groups 
were calculated using the Fisher’s exact test or chi-square 
test. INSTAT GraphPad Prism 5.0 software for Windows 
was used in the statistical analysis.
Results
The 156 treated patients with NG, despite a low dose of 
thyroxine (median T4 = 1.17 µg/kg/day), had a median 
TSH of 0.079 mU/L (IQ1–IQ3 = 0.02–0.30 mU/L) (‘non-
conventional’ suspicion, group 1). After withdrawal of 
thyroxine treatment, TSH level was restored into normal 
range (median TSH = 1.21 mU/L). All these patients 
underwent scants, which confirmed the diagnosis of 
thyroid functional autonomy in 101/156 patients (64.7%), 
while in the remaining 55 patients (35.3%) the suspicion 
was not confirmed (Fig. 1). Interestingly, the median TSH, 
without thyroxine treatment, was not different in the 
patients with or without confirmed areas of autonomy 
(median TSH: 1.28 vs 1.12 mU/L; P = ns). In contrast, 
both the early iodine uptake at 4th hour (16.27 vs 13%; 
P = 0.0378) and the total iodine uptake at 24th hour (31.91 
vs 25.28%; P = 0.0006) were significantly different in 
confirmed and non-confirmed patients (Fig. 2A).
Table 2 Age-related characteristics of thyroxine treated 
patients.
Group 1
Reference  
group P
<60 years (n) 114 88
Median TSH with T4 (mU/L) 0.08 0.20 <0.0001
T4 dose/weight (µg/kg/day) 1.20 1.56 <0.0001
>60 years (n) 42 36
Median TSH with T4 (mU/L) 0.07 0.22 0.0727
T4 dose/weight (µg/kg/day) 0.93 1.33 <0.0001
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These data were compared with those obtained in 
the other groups of patients investigated on the basis of 
‘fairly conventional’ and ‘conventional’ suspicion. The 
188 patients with NG and ‘fairly conventional’ suspicion 
of thyroid functional autonomy (group 2) showed a 
median TSH = 0.80 mU/L (IQ1–IQ3: 0.60–0.95 mU/L). In 
99/188 patients (52.6%) the suspicion of an autonomously 
functioning area was confirmed and excluded in the 
remaining 89. Unlike group 1, the median iodine uptake 
at 4th hour and 24th hour was similar, 12.34 vs 12.83% 
and 26% vs 26%, respectively, in the confirmed and 
in non-confirmed patients (P = ns) (Fig.  2B). In the 146 
patients with NG and ‘conventional’ suspicion of thyroid 
functional autonomy (group 3) a median TSH level of 
0.12 mU/L (IQ1–IQ3: 0.03–0.26 mU/L) was observed. In 
119/146 patients (81.5%) the presence of an autonomously 
functioning area was confirmed by the TS, while in 27 
was excluded. The median radioiodine uptake at 4th hour 
was significantly higher (P = 0.013) in those with proven 
areas of autonomy than in those non-confirmed (median 
uptake: 14% vs 11.9%). A similar trend was observed even 
at 24th hour (28.16% vs 25.09%; P = 0.0094) (Fig. 2C).
So far, the percentage of patients with confirmed 
thyroid autonomy was higher in group 3 (low serum 
TSH) than in patients with normal TSH (groups 1 and 2) 
(chi-square P < 0.0001) (Fig.  1), whereas the percentage 
of thyroid autonomy in group 1 (‘non-conventional’ 
approach) (64.7%) is equal to the one in group 2 and 3 
pooled together (‘fairly’ and ‘conventional’ approach) 
(65%) (Fisher’s exact test: P = 0.9192).
Figure 2
The median iodine uptake at 4th and 24th hour in patients 
with confirmed areas of autonomy and in those without 
diagnostic confirmation in the study groups. Data were 
analysed by nonparametric Mann–Whitney U test.
Figure 1
Distribution of percentages of patients with confirmed areas 
of autonomy in the study groups. Data were analysed by 
nonparametric Mann–Whitney U test.
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Owing to the fact that autonomously functioning areas 
is highly associated with cardiac arrhythmias (tachycardia, 
extrasystoles, atrial fibrillation) (9), the presence of these 
disorders were investigated in the whole study group. A 
total of 85 (69F/16M; median age: 64 years) out of 490 
patients with NG (17.3%) showed heart rhythm disorders. 
Notably, a cardiac arrhythmia has been found in 22/156 
patients (14.1%) in group 1, in 39/188 patients (20.7%) in 
group 2 and in 24/146 patients (16.4%) in group 3, being 
these differences not statistically significant (chi-square 
test: P = 0.2537) (Table 3). Also no difference (P = 0.2755) 
was observed by merging data from ‘non-conventional’ 
and ‘fairly conventional’ suspicion, showing similar TSH 
values, and comparing them with data in patients with 
low serum TSH.
Among the 319 patients with proven areas of thyroid 
autonomy, 62 patients (50F/12M; median age: 65 years) 
had a cardiac arrhythmias (19.4%), representing 72.9% of 
all patients (62/85) with heart rhythm disorders (Fig. 3). 
Analysis of the subgroups revealed that there were no 
differences in rate of cardiac arrhythmias among the 
groups (chi-square test: P = 0.2003) (Table 3). Noticeably, 
the median age was significantly higher in patients with 
low serum TSH (group 3; median age: 70 years) than in 
patients with normal TSH, both untreated (group 2; 
median age: 64  years; P = 0.0103) and treated with T4 
(group 1; median age: 55 years; P = 0.0019) (Table 3).
Overall, among 85 patients with heart rhythm 
disorders, some 30 patients (35%) had one or more events 
of atrial fibrillation (paroxysmal or chronic). In 5 of these, 
atrial fibrillation was not related with thyroid disorder and 
therefore it represented the 40% (25/62) of all arrhythmias 
diagnosed in patients with thyroid autonomy. Again, 
the rate of atrial fibrillation was similarly detected by 
conventional and non-conventional approaches (group 
1: 7/101 (6.93%); group 2: 9/99 (9.1%); group 3: 9/119 
(7.56%); chi-square test: P = 0.8425] (Table 3).
Discussion
The findings of this study have shown that (a) the low 
serum TSH level is a reliable but belated index associated 
with hyperfunctioning nodules; (b) normal serum TSH 
may be also associated with autonomous thyroid areas; (c) 
by the described ‘non-conventional’ approach, we have 
identified a substantial percentage of occult autonomous 
areas as well; (d) heart arrhythmias were not related to 
serum TSH but rather to the presence of autonomous 
areas, even occult.
In iodine-deficient areas, the natural history of 
nontoxic goitre encompasses its functional transition 
to thyroid autonomy (2, 34), which increases with 
age and may be recognizable in some 15% of elderly 
patients (35). This study agreed with the other reports 
stating that low serum TSH is a good predictor for the 
existence of thyroid areas with functional autonomy 
(14). Nevertheless, this study demonstrated that the 
TS, performed in carefully selected patients with 
normal TSH, detects early a significant number of 
patients with autonomous thyroid function areas and 
cardiac arrhythmias. This is not fully in keeping with 
Recommendation 2 (moderate quality evidence) in 
Table 3 Cardiac arrhythmias in the study groups.
n (F/M) Median age, years Group 1 Group 2 Group 3 P
All patients with cardiac arrhythmias (CA) 85 (69/16) 64 22/156 39/188 24/146 0.2537
Patients with CA and confirmed areas of autonomy 62 (50/12) 65 16/101 25/99 21/119 0.2003
Patients with atrial fibrillation and confirmed areas  
of autonomy
25 (20/5) 69 7/101 9/99 9/119 0.8425
Figure 3
Overview of arrhythmias and atrial fibrillation in patients with 
or without proven areas of autonomy.
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the ATA thyroid nodules guidelines which support the 
notion that scintiscan should be performed only when 
serum TSH is low (14). However, the recognition of these 
hyperfunctioning areas through that approach may not 
be early enough; recent studies, in fact, demonstrated 
that thyroid functional autonomy may exist even 
in patients with normal serum TSH levels and our 
results showed that this occurs several years before the 
appearance of low serum TSH. Coexistence of normal 
serum TSH levels and AFTN may occur in patients with 
apparently euthyroid goitre and in those with goitre 
associated with Hashimoto’s thyroiditis (6, 15, 36, 37). 
Indeed, in euthyroid goitres, small/subcentimetric areas 
of ‘hot’ thyroid tissue partially inhibit the remaining 
follicles, but the little amount of autonomous tissue 
and/or the low synthesis rate of iodothyronines prevent 
TSH suppression (6, 15). Similarly, in patients with 
untreated Hashimoto’s thyroiditis, the hypothyroidism, 
due to the progressive autoimmune destruction of 
thyroid tissue, is counteracted by the presence of one or 
more autonomous areas (36). The final balance among 
these opposite functional activities may sometime 
lead to normal TSH level (36). These areas of thyroid 
autonomy may remain occult for years (34), but the 
risk of developing hyperthyroidism may occur in both 
cases (6, 36) and so novel and easy diagnostic tools are 
needed to identify them at earlier stages.
On this ground, our data suggest that hyper-
responsiveness to thyroxine treatment may be useful to 
suspect the presence of an occult autonomous thyroid 
areas at an early stage. We used a similar approach when 
we studied patients with T4 malabsorption (22, 23, 38, 
39): in that case, TSH levels higher than expected led us 
to look for occult gastrointestinal disorders while in this 
study, a TSH lower than expected helped us to detect 
functional thyroid autonomy. This ‘non-conventional’ 
approach is as efficient as the conventional methods; 
in fact, the diagnosis of thyroid functional autonomy 
has been confirmed in about two-third of patients who 
hyper-responded to thyroxine treatment, a fraction 
similar to the one recorded with the conventional 
approach. Noticeably, after T4 treatment withdrawal, 
these patients had a normal TSH level, showing that 
this approach identified thyroid autonomy when still 
in an occult phase.
Arrhythmias are a major concern in patients with 
subclinical or overt hyperthyroidism, since their 
prevalence is greatly increased in these patients as 
compared with general population (7, 13). The linkage 
between autonomous functioning areas and cardiac 
arrhythmias, independently from thyroid function, is 
as yet scarcely described. Our study shows that one-fifth 
of patients with thyroid autonomously functioning 
areas have cardiac arrhythmias and some one-tenth 
has atrial fibrillation. It should be emphasized that the 
number of arrhythmias and that of atrial fibrillation 
were similar in patients with low and normal serum 
TSH, despite patients with low TSH were older, in 
agreement with the literature (40). Based on these data, 
thyroid functional autonomy may represent in itself 
a risk factor for atrial fibrillation, even when serum 
TSH is normal. Interestingly, there was no whatsoever 
difference in the frequency of arrhythmias and atrial 
fibrillation depending on the approach used. To note, 
the non-conventional approach (hyper-responsiveness 
to thyroxine treatment) to thyroid autonomy has been 
proven equivalent to conventional approach (low TSH 
or normal TSH with symptoms), even in detecting 
cardiac arrhythmias.
In conclusion, this study shows that the hyper-
responsiveness to thyroxine treatment should induce 
the suspicion of a thyroid functional autonomy at an 
early stage, allowing to detect autonomous functioning 
areas in apparently euthyroid patients. Cardiac 
arrhythmias, and chiefly atrial fibrillation, can be also 
associated to occult thyroid functional autonomy, 
though TSH would be normal. These data indicated that 
a low serum TSH may be not an early and exhaustive 
marker to diagnose thyroid functional autonomy and 
related arrhythmias.
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